Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 Sep 09

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 Sep 09

DOI: 10.23736/S1824-4785.20.03277-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Copper, PET/CT and prostate cancer. A systematic review of the literature

Arnoldo PICCARDO 1 , Martina UGOLINI 1, Sergio RIGHI 2, Gianluca BOTTONI 1, Angelina CISTARO 1, Francesco PAPARO 3, Luca GIOVANELLA 3, Laura EVANGELISTA 4

1 Department of Nuclear Medicine, E.O. Ospedali Galliera, Genoa, Italy; 2 Medical Physics Department, E.O. Ospedali Galliera, Genoa, Italy; 3 Department of Radiology, E.O. Ospedali Galliera, Genoa, Italy; 4 Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 5 Nuclear Medicine Unit, Department of Medicine, DIMED, University of Padua, Padua, Italy


PDF


Copper is an essential element that plays an important role in both cancer development and growth. Indeed, high levels of copper have been found in prostate cancer (PCa), and this finding have paved the way for the use of this element as a target for positron emission tomography (PET) imaging. Copper64 (64Cu) can be used alone, as 64CuCl2, and also as a precursor for the in vitro radio-labelling of specific carriers for PET imaging in PCa, (e.g. associated to prostate-specific membrane antigen: PSMA). The use of 64Cu-PSMA can yield late acquisitions in which PET images are characterized by a higher target-to-background ratio. At the same time, the shorter positron range of 64Cu provides high spatial resolution, which leads to better detection of small lesions. In this context, the aim of this review was to systematically review studies evaluating the identification of PCa in humans by means of 64CuCl2 and other PET tracers radiolabelled with 64Cu.


KEY WORDS: Copper; 64Cu; PET/CT; Elderly and prostate cancer

top of page